Mallinckrodt was Downgraded to a Hold Rating at Mizuho Securities

By Carrie Williams

In a report released today, Irina Rivkind Koffler from Mizuho Securities downgraded Mallinckrodt (NYSE: MNK) to Hold, with a price target of $40. The company’s shares closed yesterday at $36.45, close to its 52-week low of $34.51.

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 15.9% and a 50.4% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Apricus Biosciences Inc, and Sucampo Pharmaceuticals.

Currently, the analyst consensus on Mallinckrodt is Strong Buy and the average price target is $66.20, representing an 81.6% upside.

In a report issued on September 6, Morgan Stanley also downgraded the stock to Hold with a $40 price target.

Mallinckrodt’s market cap is currently $3.54B and has a P/E ratio of 9.44. The company has a book value ratio of 0.6948.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the following segments: Specialty Brands, Specialty Generics, and Nuclear Imaging.